Bortezomib Boric Acid Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Bortezomib, a proteasome inhibitor used in cancer treatment, is unstable under standard conditions, making it difficult to purify and formulate into a stable therapeutic product due to its tendency to form anhydrides and oxidize, which limits its shelf life and therapeutic effectiveness.
Innovation Solution
A composition of bortezomib combined with boric acid in a solid form, with a mass ratio of boric acid to bortezomib ranging from 1:1 to 10:1, which stabilizes bortezomib during storage and allows for rapid reconstitution when administered, maintaining therapeutic effectiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bortezomib is stored under standard conditions, then it is easy to handle and administer, but it forms anhydrides and oxidizes, leading to degradation and loss of therapeutic effectiveness
Solution Approach 1:
The patent introduces boric acid as an intermediary substance that mediates between bortezomib and the degrading environment. Boric acid forms a protective complex with bortezomib, preventing direct contact with oxygen and moisture that would otherwise cause oxidation and anhydride formation. This intermediary approach allows bortezomib to be stored under ambient conditions without specialized inert atmospheres or extreme temperature controls.
Solution Approach 2:
The patent creates a composite formulation consisting of bortezomib combined with boric acid and mannitol in specific ratios. This composite material leverages the stabilizing properties of boric acid (which forms protective boronate esters with the boronic acid group of bortezomib) and mannitol (which provides a protective matrix and prevents crystallization). The composite structure physically and chemically protects bortezomib from degradation pathways.
2Duration of action of stationary object
If bortezomib is combined with sugar compounds like mannitol for stabilization, then shelf life is extended, but reconstitution time increases and therapeutic effectiveness may be compromised
Solution Approach 1:
The patent optimizes the concentration parameters of boric acid (0.1-10 mM) and mannitol (1-100 mM) to achieve the minimum effective stabilization without excessive reconstitution times. By carefully controlling these parameters, the formulation achieves stability enhancement while maintaining rapid reconstitution capability. The specific ratio ranges are determined through systematic parameter optimization to balance stability and solubility requirements.
3Stability of the object's composition
If bortezomib is formulated with high concentrations of stabilizing agents, then stability is improved, but impurity levels increase and purification becomes more difficult
Solution Approach 1:
The patent employs partial action by using sub-stoichiometric amounts of boric acid and mannitol relative to what would be required for complete protection. Instead of using excess stabilizing agents that would create purification problems, the formulation uses optimized concentrations that provide sufficient stabilization through the synergistic effect of boric acid-bortezomib complex formation and mannitol matrix protection, minimizing impurity formation while maintaining stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bortezomib-boric acid composition provides extended stability at ambient temperatures with minimal degradation, achieving rapid reconstitution and maintaining therapeutic efficacy comparable to conventional formulations, while reducing impurity levels and reconstitution time.
Implementation Method 1
bortezomib forms a boronate ester with such a di-hydroxyl compound, and that this ester is more stable to air and to dehydration than bortezomib alone
Implementation Method 2
lyophilizing the liquid mixture
Data Source
AI summary
A bortezomib composition includes bortezomib and boric acid in a mass ratio of boric acid to bortezomib is from 1:1 to 10:1. The composition is a solid, and may be prepared by forming a liquid mixture including a solvent, bortezomib and boric acid, and lyophilizing the liquid mixture.